Abingdon, UK - OBN, the Membership organisation supporting the UK’s innovative life sciences companies, announced today the appointment of Mark Hooper as the new Head of Business Development with immediate effect.

Mark has over 15 years’ experience in the life sciences industry, with a thorough knowledge of the pharmaceutical drug development process, from discovery to development as well as clinical trials and commercial sales. He started work as a research chemist and progressed to be Technical Sales Manager at Johnson Matthey following which he worked in various Director roles at Pharmaterials, a contract research organisation, including business development, project management and screening, running an analytical/QC group and supporting patent disputes in the high court. More recently, he was Director at Conversis Medical, a translation company, where his business development role covered clinical trials, patient engagement and commercial launch. Mark has an MBA from Warwick, a DPhil and BA (Chem) from Oxford and carried out PostDoc studies at Yale.

John Harris, CEO, OBN said: “We are delighted that Mark has joined us in this key role, his background perfectly complements the many facets of OBN and we are looking forward to reaping the rewards of his experience.”

Mark Hooper commented: “I am excited to be part of OBN as I passionately believe that great innovation coupled with solid investment and dynamic support makes for a thriving life sciences sector, of which the UK is a world leader.”